Generic Vaniqa

Vaniqa Eflornithineis used to delay the growth of unwanted facial hair in women. It inhibits an enzyme required in the skin for hair growth but does not remove hair. Although it has been widely used in women, but its safety level has not been proved.

Some clinical study shows occurrence frequencies of adverse events reported for most body systems were similar in Vaniqa Eflornithine hydrochloride) Cream, 13.9% and vehicle control groups. The most common adverse events related to treatment with VANIQA were skin-related. Medicines and their possible side effects can affect individual people in different ways.

Less than 1% of patients getting VANIQA treatment reported skin adverse events such as bleeding skin, cheilitis, contact dermatitis, swelling of lips, herpes simplex, numbness and rosacea. Reported side effects were primarily minor in intensity and generally resolved without medical treatment or discontinuation of VANIQA. Only 2% of subjects discontinued studies because of an adverse event related to use of VANIQA.

A dermal fertility and early embryonic development study made on rats treated with Vaniqa Eflornithine showed no adverse reproductive effects at doses up to 450 mg/kg (29X the MRHD based on BSA). In a peri- and postnatal study in rats, eflornithine given in the drinking water caused maternal toxicity and reduced pup weights at doses of at least 625 mg/kg (40X the MRHD based on BSA) and a slightly reduced fertility index, which was considered to be of questionable biological significance, at 1698 mg/kg (110X the MRHD based on BSA).

A number of side effects associated with Vaniqa Eflornithine are: skin bleeding or blistering, cold sores, acne, skin irritation – burning, stinging, redness of the skin, rash, ingrown hair, flushing of skin, dry or numb lips, dry skin, abnormal hair texture and growth, changes in skin pigmentation, itchy dermatitis and skin cysts.

All people using this medicine will not experience all the side effects. In fact some may experience minor side effects while other no side effects at all.

For more information about any other possible risks of this medicine, please read the information provided with the medicine or consults your doctor or pharmacist.

Vaniqa Eflornithine has not been reported consistently to have problem with laboratory test.

In an open-label study, some patients showed a rise in their transaminases; but, the clinical significance of these findings is not clear.

It is not identified if VANIQA has any interaction with other topically applied drug products.

Certain medicines are contraindicated for use during pregnancy or breastfeeding. On the other hand, other medicines may be safely used in pregnancy or breastfeeding on condition that the benefits to the mother outweigh the risks to the unborn baby. Always notify your doctor if you are pregnant or planning a pregnancy, before using any medicine.

The safety of this medicine for use during pregnancy has not been recognized. It should not be used by pregnant women or by those planning pregnancy. So the patient can use any alternative method of hair removal.

It is not well-known if Vaniqa Eflornithine excretes into breast milk, but it is possible that it may. Accordingly, it should not be used by mothers who are breastfeeding.